The MA-ncRNAs Axis in Diabetes Complications: Novel Mechanism and Therapeutic Potential

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Jul 9

PMID 38978623

Authors

Siming Yu

Chunsheng Li

Xinxin Lu

Zehui Han

Yue Li

Xingxing Yuan

Dandan Guo

Affiliations

Soon will be listed here.

Abstract

Diabetes, a multifaceted metabolic disorder, poses a significant global health burden with its increasing prevalence and associated complications, such as diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, and diabetic angiopathy. Recent studies have highlighted the intricate interplay between N-methyladenosine (mA) and non-coding RNAs (ncRNAs) in key pathways implicated in these diabetes complications, like cell apoptosis, oxidative stress, and inflammation. Thus, understanding the mechanistic insights into how mA dysregulation impacts the expression and function of ncRNAs opens new avenues for therapeutic interventions targeting the mA-ncRNAs axis in diabetes complications. This review explores the regulatory roles of mA modifications and ncRNAs, and stresses the role of the mA-ncRNA axis in diabetes complications, providing a therapeutic potential for these diseases.

References

Dai F, Wu Y, Lu Y, An C, Zheng X, Dai L . Crosstalk between RNA mA Modification and Non-coding RNA Contributes to Cancer Growth and Progression. Mol Ther Nucleic Acids. 2020; 22:62-71. PMC: 7486578. DOI: 10.1016/j.omtn.2020.08.004. View

Cole J, Florez J . Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020; 16(7):377-390. PMC: 9639302. DOI: 10.1038/s41581-020-0278-5. View

Shan L, Guo M, Dai Y, Wei L, Zhang W, Gao J . Comprehensive analysis of m6A modification lncRNAs in high glucose and TNF-α induced human umbilical vein endothelial cells. Medicine (Baltimore). 2023; 102(10):e33133. PMC: 9997758. DOI: 10.1097/MD.0000000000033133. View

Feng X, Yang X, Zhong Y, Cheng X . The role of ncRNAs-mediated pyroptosis in diabetes and its vascular complications. Cell Biochem Funct. 2024; 42(2):e3968. DOI: 10.1002/cbf.3968. View

Yue Y, Liu J, Cui X, Cao J, Luo G, Zhang Z . VIRMA mediates preferential mA mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018; 4:10. PMC: 5826926. DOI: 10.1038/s41421-018-0019-0. View

Vijayalalitha R, Archita T, Juanitaa G, Jayasuriya R, Amin K, Ramkumar K . Role of Long Non-Coding RNA in Regulating ER Stress Response to the Progression of Diabetic Complications. Curr Gene Ther. 2022; 23(2):96-110. DOI: 10.2174/1566523222666220801141450. View

Ismail A, El-Mahdy H, Eldeib M, Doghish A . miRNAs as cornerstones in diabetic microvascular complications. Mol Genet Metab. 2022; 138(1):106978. DOI: 10.1016/j.ymgme.2022.106978. View

Zhang Z, Theler D, Kaminska K, Hiller M, De La Grange P, Pudimat R . The YTH domain is a novel RNA binding domain. J Biol Chem. 2010; 285(19):14701-10. PMC: 2863249. DOI: 10.1074/jbc.M110.104711. View

Mattick J, Rinn J . Discovery and annotation of long noncoding RNAs. Nat Struct Mol Biol. 2015; 22(1):5-7. DOI: 10.1038/nsmb.2942. View

10.

Li Y, Li L, Liu Y, Hu L, Yan Y . Identification of Metabolism-Related Proteins as Biomarkers of Insulin Resistance and Potential Mechanisms of mA Modification. Nutrients. 2023; 15(8). PMC: 10146912. DOI: 10.3390/nu15081839. View

11.

Kim L, Park S, Nam E, Kim Y, Heo T, Kim H . LncRNA SNHG4 Modulates EMT Signal and Antitumor Effects in Endometrial Cancer through Transcription Factor SP-1. Biomedicines. 2023; 11(4). PMC: 10135476. DOI: 10.3390/biomedicines11041018. View

12.

Kasowitz S, Ma J, Anderson S, Leu N, Xu Y, Gregory B . Nuclear m6A reader YTHDC1 regulates alternative polyadenylation and splicing during mouse oocyte development. PLoS Genet. 2018; 14(5):e1007412. PMC: 5991768. DOI: 10.1371/journal.pgen.1007412. View

13.

Li C, Su F, Liang Z, Zhang L, Liu F, Fan W . Macrophage M1 regulatory diabetic nephropathy is mediated by m6A methylation modification of lncRNA expression. Mol Immunol. 2022; 144:16-25. DOI: 10.1016/j.molimm.2022.02.008. View

14.

Cheng C, Yu F, Yuan G, Jia J . Update on N6-methyladenosine methylation in obesity-related diseases. Obesity (Silver Spring). 2023; 32(2):240-251. DOI: 10.1002/oby.23932. View

15.

Zhou H, Kuang H . Circular RNAs: Novel target of diabetic retinopathy. Rev Endocr Metab Disord. 2021; 22(2):205-216. DOI: 10.1007/s11154-021-09646-0. View

16.

Ke S, Alemu E, Mertens C, Gantman E, Fak J, Mele A . A majority of m6A residues are in the last exons, allowing the potential for 3' UTR regulation. Genes Dev. 2015; 29(19):2037-53. PMC: 4604345. DOI: 10.1101/gad.269415.115. View

17.

Fan W, Pang H, Xie Z, Huang G, Zhou Z . Circular RNAs in diabetes mellitus and its complications. Front Endocrinol (Lausanne). 2022; 13:885650. PMC: 9376240. DOI: 10.3389/fendo.2022.885650. View

18.

Wang F, Bai J, Wang D, Zhang X, Xue J, Chen H . METTL3/YTHDF2 m6A axis mediates the progression of diabetic nephropathy through epigenetically suppressing PINK1 and mitophagy. J Diabetes Investig. 2023; 15(3):288-299. PMC: 10906015. DOI: 10.1111/jdi.14113. View

19.

Roy D, Modi A, Khokhar M, Sankanagoudar S, Yadav D, Sharma S . MicroRNA 21 Emerging Role in Diabetic Complications: A Critical Update. Curr Diabetes Rev. 2020; 17(2):122-135. DOI: 10.2174/1573399816666200503035035. View

20.

Shu H, Zhang Z, Liu J, Chen P, Yang C, Wu Y . Circular RNAs: An emerging precise weapon for diabetic nephropathy diagnosis and therapy. Biomed Pharmacother. 2023; 168:115818. DOI: 10.1016/j.biopha.2023.115818. View